Atossa Therapeutics Reflects on 2025 Progress with Ambitious Goals for 2026

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company known for its innovative therapies in various medical fields, recently addressed its shareholders in a letter from Steven Quay, M.D., Ph.D., the President and CEO of the Company. This letter detailed significant achievements in 2025 and outlined an ambitious outlook for 2026.

Reflecting on 2025 Achievements

In 2025, Atossa made remarkable strides in advancing its flagship therapy, (Z)-endoxifen, particularly in oncology. The year was characterized by refined strategic direction, focusing on navigating the regulatory landscape effectively and targeting high unmet medical needs, particularly in breast cancer and rare diseases. Key milestones included a pivotal Type C meeting with the FDA that clarified expedited pathways for the development of (Z)-endoxifen, especially within the context of breast cancer treatment.

The company's ongoing clinical investigations included the I-SPY 2 study, which tested (Z)-endoxifen either alone or in combination with reputable therapies like abemaciclib and elagolix. Preliminary results have been optimistic, showing (Z)-endoxifen's potential to lessen tumor activity in women diagnosed with ER+/HER- breast cancer.

Moreover, Atossa made a conscious decision to pause the development of (Z)-endoxifen for Metastatic Breast Cancer, shifting focus towards other indications that promise a better return on investment.

Exploring New Therapeutic Avenues

As 2025 progressed, Atossa recognized the broader therapeutic potential of (Z)-endoxifen, exploring its application in serious non-oncology diseases such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS). The findings indicated that (Z)-endoxifen might play a crucial role in addressing muscle preservation and inflammatory conditions, showcasing the compound's versatility beyond oncology. Notably, the FDA granted rare pediatric disease and orphan drug designations for DMD, signaling a strategic breakthrough for Atossa.

Intellectual Property and Leadership Enhancements

Throughout 2025, Atossa reinforced its intellectual property estate by successfully obtaining a U.S. patent related to enteric oral formulations of (Z)-endoxifen. This is a crucial development that solidifies Atossa's commitment to maintaining its innovative edge in therapeutic delivery methods.

The addition of experienced team members also strengthened the company’s operational capacity, ensuring a focus on regulatory execution and commercial readiness. Key appointments included Janet R. Rea as Senior Vice President, overseeing late-stage programs, and Mark Daniel as CFO, steering financial strategy.

2026: Focused and Strategic

As they look toward 2026, Atossa aims to push forward with regulatory execution based on feedback from their 2025 FDA interactions. The company plans to leverage its findings from the I-SPY 2 studies to explore partnerships that may enhance the reach and effectiveness of (Z)-endoxifen. Substantial efforts will also be placed on non-oncology opportunities, reflecting a balanced approach that maximizes shareholder value.

Conclusion

Entering 2026, Atossa Therapeutics holds a clear roadmap aimed at sustaining its progression in oncology while exploring vital non-oncology fields. The commitment to developing novel therapies that meet substantial patient needs remains central to Atossa’s mission. With a robust financial health and the potential for capitalization on various promising fronts, Atossa Therapeutics is well-positioned to make strides in both regulatory milestones and clinical successes in the upcoming year.

For more information on Atossa's ongoing projects and studies, visit Atossa Therapeutics.